Farallon Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Farallon Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,024,472	Closed	-$119M	–	196
2023 Q4	$119M	Buy	2,024,472 +1,023,472	+102%	+$57.5M	0.54%	41
2023 Q3	$43.6M	Buy	+1,001,000	New	+$35.7M	0.2%	61
2021 Q4	–	Sell	-238,718	Closed	-$42.2M	–	322
2021 Q3	$42.2M	Sell	238,718 -661,282	-73%	-$106M	0.2%	80
2021 Q2	$145M	Buy	900,000 +50,000	+6%	+$8.03M	0.59%	44
2021 Q1	$146M	Sell	850,000 -25,000	-3%	-$4.95M	0.72%	40
2020 Q4	$192M	Hold	875,000	–	–	1.16%	35
2020 Q3	$145M	Buy	875,000 +225,000	+35%	+$30.8M	1.01%	38
2020 Q2	$74.2M	Buy	650,000 +50,000	+8%	+$4.85M	0.59%	45
2020 Q1	$46.1M	Buy	600,000 +425,000	+243%	+$38.1M	0.4%	45
2019 Q4	$22.6M	Sell	175,000 -125,000	-42%	-$12.1M	0.15%	80
2019 Q3	$23.4M	Sell	300,000 -695,000	-70%	-$65.2M	0.18%	70
2019 Q2	$102M	Sell	995,000 -205,000	-17%	-$16M	0.67%	33
2019 Q1	$88M	Sell	1,200,000 -100,000	-8%	-$6.8M	0.66%	42
2018 Q4	$55.1M	Buy	1,300,000 +425,000	+49%	+$16.9M	0.4%	45
2018 Q3	$41.2M	Buy	875,000 +131,500	+18%	+$7.32M	0.24%	52
2018 Q2	$36.7M	Buy	743,500 +473,500	+175%	+$17.9M	0.23%	56
2018 Q1	$8.29M	Buy	+270,000	New	+$7.49M	0.06%	79

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Farallon Capital Management's MRTX Position: Q1 2024 in Review

Farallon Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 2,024,472 shares — an estimated $119M sold.

Farallon Capital Management first reported a position in MRTX in Q1 2018 and held it in 17 quarters. The position peaked at $192M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Farallon Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Farallon Capital Management sold 2,024,472 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $119M.
Farallon Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 17 quarters.
Farallon Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $192M in Q4 2020.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Farallon Capital Management's 13F filing for Q1 2024, filed 15 May 2024.